Subtype
Digestive System Carcinoma
CI-CAN-00000812Explore in graph →
2,123 active trials27 approved drugs139 evidence items
- NCIt
- C96963
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000812Explore in graph →
Clinical trials
7,540 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (884)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06048133 | Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) | active not recruiting | Phase 2 | 33 | Nataliya UbohaOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04230759 | Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group(RADIANCE) | active not recruiting | Phase 2 | 180 | Goethe UniversityOTHER | 3 | Aug 14, 2026 |
| clinicaltrials |
| NCT04550481 | Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study | active not recruiting | Phase 2 | 35 | Northwestern UniversityOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05211323 | A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer | active not recruiting | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05722288 | Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers | active not recruiting | Phase 2 | 49 | City of Hope Medical CenterOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06399757 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 100 | Apollo Therapeutics LtdINDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04115163 | Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer | active not recruiting | Phase 2 | 67 | Anne NoonanOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04594772 | Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma | active not recruiting | Phase 2 | 32 | University of CincinnatiOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04887805 | Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer | active not recruiting | Phase 2 | 28 | City of Hope Medical CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06792435 | XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. | active not recruiting | Phase 1 / Phase 2 | 240 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT03851614 | Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors(DAPPER) | active not recruiting | Phase 2 | 90 | University Health Network, TorontoOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03859128 | Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection(JUPITER 04) | active not recruiting | Phase 2 / Phase 3 | 427 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03844620 | Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer | active not recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05713838 | Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery | active not recruiting | Phase 2 | 32 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT02965703 | Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma | active not recruiting | Phase 2 | 81 | National Cancer Institute (NCI)NIH | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06168812 | A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer | active not recruiting | Phase 2 | 29 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT02519348 | A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma | active not recruiting | Phase 2 | 433 | MedImmune LLCINDUSTRY | 9 | Aug 5, 2026 | clinicaltrials |
| NCT04083599 | GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 350 | GenmabINDUSTRY | 12 | Aug 4, 2026 | clinicaltrials |
| NCT05564403 | Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) | active not recruiting | Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT03878095 | Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors | active not recruiting | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Aug 3, 2026 | clinicaltrials |
| NCT02888743 | Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 110 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT06921928 | Study for AZD4360 in Participants With Advanced Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 31 | AstraZenecaINDUSTRY | 5 | Jul 31, 2026 | clinicaltrials |
| NCT03641313 | Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer | active not recruiting | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06710132 | Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) | active not recruiting | Phase 1 / Phase 2 | 184 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 10 | Jul 30, 2026 | clinicaltrials |
| NCT06506955 | Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. | active not recruiting | Phase 2 / Phase 3 | 15 | Taiho Oncology, Inc.INDUSTRY | 5 | Jul 28, 2026 | clinicaltrials |
| NCT06914687 | Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma | active not recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT02595424 | Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas | active not recruiting | Phase 2 | 67 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jul 27, 2026 | clinicaltrials |
| NCT05476796 | Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer(LOGICAN) | active not recruiting | Phase 2 | 118 | UNICANCEROTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06193733 | Dendritic Cell Vaccination to Prevent Hepatocellular Carcinoma Recurrence After Liver Resection - Phase II Clinical Trial | active not recruiting | Phase 2 | 74 | Chang Gung Memorial HospitalOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06157892 | A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors | active not recruiting | Phase 2 | 54 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 10 | Jul 22, 2026 | clinicaltrials |
| NCT04599140 | SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial | active not recruiting | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05194293 | Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer | active not recruiting | Phase 2 | 4 | Academic and Community Cancer Research UnitedOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07711470 | Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC(SCOPE) | active not recruiting | Phase 2 | 140 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT03087071 | Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer | active not recruiting | Phase 2 | 59 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03599752 | Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases | active not recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 2 | Jul 16, 2026 | clinicaltrials |
| NCT03856658 | Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases | active not recruiting | Phase 2 | 14 | Corewell Health WestOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06129604 | Pilot Window of Opportunity Trial (POET) | active not recruiting | Phase 2 | 10 | University of OklahomaOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06679985 | A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma | active not recruiting | Phase 2 | 72 | Coherus Oncology, Inc.INDUSTRY | 6 | Jul 15, 2026 | clinicaltrials |
| NCT03816163 | A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer | active not recruiting | Phase 2 | 393 | Astellas Pharma Global Development, Inc.INDUSTRY | 13 | Jul 14, 2026 | clinicaltrials |
| NCT04233866 | Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread | active not recruiting | Phase 2 | 176 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05355298 | ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 62 | Amplia Therapeutics LimitedINDUSTRY | 2 | Jul 10, 2026 | clinicaltrials |
| NCT05726864 | A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors(AMPLIFY-7P) | active not recruiting | Phase 1 / Phase 2 | 158 | Elicio TherapeuticsINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06096779 | A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis(Kirros) | active not recruiting | Phase 2 | 30 | Genentech, Inc.INDUSTRY | 2 | Jul 10, 2026 | clinicaltrials |
| NCT05632328 | AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC | active not recruiting | Phase 2 | 24 | Bruno BockornyOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT05308446 | Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation | active not recruiting | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 2 | Jul 8, 2026 | clinicaltrials |
| NCT06165380 | Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma | active not recruiting | Phase 2 | 43 | Li ZhangOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05709574 | Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer | active not recruiting | Phase 2 | 11 | University of ArizonaOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05710406 | Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer | active not recruiting | Phase 2 / Phase 3 | 1 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05724563 | Domvanalimab and Zimberelimab in Advanced Liver Cancers | active not recruiting | Phase 2 | 58 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07682376 | Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | active not recruiting | Phase 2 | 96 | Harbin Medical UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 17, 2026source: clinicaltrials